The Aenova Group publishes its 2021 Annual Report today.
The key figures 2021 of Aenova at a glance:
€107 million adjusted EBITDA*
€125 million in additional new projects
89 % on-time deliveries (annual average on-time delivery, OTD)
"2021 was a challenging year for many industries, including the pharmaceutical industry," said Jan Kengelbach, CEO of Aenova Group. "Not unlike many of our customers, suppliers and market peers, we had to deal with several waves of pandemic-related restrictions, which definitely impacted our operational business. However, looking back, we can positively summarize that the entire Aenova Group has shown a very high resilience and that we have stayed on track with our transformation program, even though our financial performance was slightly below the previous year," Kengelbach added.
Expressed in figures, this means a year-on-year decline in sales of 5.8% (2021: €697 million; 2020: €740 million). However, the Aenova Group was able to further increase the EBITDA margin from 15.1 % in the previous year to 15.3 %, thus achieving the best EBITDA margin in the entire history of the company in 2021. Thus, in 2021, Aenova's already robust financial base could be further built up.
Learn more about Aenova's 2021 achievements and milestones, as well as key events in each business unit.